CL2017002817A1 - Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue - Google Patents
Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengueInfo
- Publication number
- CL2017002817A1 CL2017002817A1 CL2017002817A CL2017002817A CL2017002817A1 CL 2017002817 A1 CL2017002817 A1 CL 2017002817A1 CL 2017002817 A CL2017002817 A CL 2017002817A CL 2017002817 A CL2017002817 A CL 2017002817A CL 2017002817 A1 CL2017002817 A1 CL 2017002817A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- mono
- inhibitors
- viral replication
- indole derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE INDOL MONO O DISUSTITUIDOS, A MÉTODOS PARA PREVENIR O TRATAR INFECCIONES VIRALES POR DENGUE USANDO DICHOS COMPUESTOS Y TAMBIÉN SE REFIERE A DICHOS COMPUESTOS PARA SU USO COMO UN MEDICAMENTO, MÁS PREFERIBLEMENTE PARA SU USO COMO UNA MEDICINA PARA TRATAR O PREVENIR INFECCIONES VIRALES POR DENGUE. LA PRESENTE INVENCIÓN SE REFIERE ADICIONALMENTE A COMPOSICIONES FARMACÉUTICAS O PREPARACIONES DE COMBINACIÓN DE LOS COMPUESTOS, A LAS COMPOSICIONES O PREPARACIONES PARA SU USO COMO UN MEDICAMENTO, MÁS PREFERIBLEMENTE PARA LA PREVENCIÓN O TRATAMIENTO DE INFECCIONES VIRALES POR DENGUE. LA INVENCIÓN TAMBIÉN SE REFIERE A PROCESOS PARA LA PREPARACIÓN DE LOS COMPUESTOS.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166900 | 2015-05-08 | ||
| EP16163342 | 2016-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002817A1 true CL2017002817A1 (es) | 2018-05-11 |
Family
ID=56026812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002817A CL2017002817A1 (es) | 2015-05-08 | 2017-11-07 | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US10696632B2 (es) |
| EP (2) | EP3294738B1 (es) |
| JP (4) | JP6752821B2 (es) |
| KR (2) | KR102610491B1 (es) |
| CN (3) | CN113045476A (es) |
| AU (2) | AU2016259677B2 (es) |
| BR (1) | BR112017023904A2 (es) |
| CA (1) | CA2981845C (es) |
| CL (1) | CL2017002817A1 (es) |
| CO (1) | CO2017012381A2 (es) |
| CR (2) | CR20200152A (es) |
| CY (1) | CY1124548T1 (es) |
| DK (1) | DK3294738T3 (es) |
| EA (1) | EA034978B1 (es) |
| EC (2) | ECSP17073878A (es) |
| ES (2) | ES2877404T3 (es) |
| GT (1) | GT201700234A (es) |
| HK (2) | HK1252446A1 (es) |
| HR (1) | HRP20210675T1 (es) |
| HU (1) | HUE054724T2 (es) |
| IL (2) | IL255430B (es) |
| JO (2) | JOP20160086B1 (es) |
| LT (1) | LT3294738T (es) |
| MD (1) | MD3294738T2 (es) |
| MX (2) | MX2020011156A (es) |
| NI (1) | NI201700137A (es) |
| PE (2) | PE20180232A1 (es) |
| PH (1) | PH12017502000A1 (es) |
| PL (1) | PL3294738T3 (es) |
| RS (1) | RS62029B1 (es) |
| SG (1) | SG10201900315SA (es) |
| SI (1) | SI3294738T1 (es) |
| SV (1) | SV2017005557A (es) |
| TW (2) | TWI744963B (es) |
| UA (1) | UA121332C2 (es) |
| UY (2) | UY39706A (es) |
| WO (1) | WO2016180696A1 (es) |
| ZA (1) | ZA202002435B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3436436B1 (en) | 2016-03-31 | 2022-05-11 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| JP6888021B2 (ja) | 2016-03-31 | 2021-06-16 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | デングウイルス複製阻害剤としての置換インドール誘導体 |
| CR20180494A (es) * | 2016-04-01 | 2019-01-29 | Janssen Pharmaceuticals Inc | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| KR102625988B1 (ko) | 2017-05-22 | 2024-01-16 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체 |
| CR20190531A (es) * | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| EP4058019A1 (en) | 2019-11-15 | 2022-09-21 | Janssen Pharmaceuticals, Inc. | Treatment and prevention of dengue disease |
| WO2022094816A1 (en) | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
| WO2022094817A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Pharmaceutical formulation |
| CN113024440B (zh) * | 2021-03-17 | 2023-05-16 | 凯莱英医药集团（天津）股份有限公司 | 连续化合成取代吲哚-2-羧酸的方法 |
| CN117616010A (zh) | 2021-06-29 | 2024-02-27 | 杨森制药公司 | 制备(s)-2-(4-氯-2-甲氧基苯基)-2-((3-甲氧基-5-(甲磺酰基)苯基)氨基)-1-(1h-吲哚-3-基)乙烯酮衍生物的方法 |
| WO2023218285A1 (en) | 2022-05-12 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Treatment or prevention of dengue viral infection |
| CN115521307B (zh) * | 2022-09-30 | 2023-09-22 | 甘肃皓天医药科技有限责任公司 | 一种5-卤代-7-氮杂吲哚的制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69830335T2 (de) | 1997-10-27 | 2006-02-02 | Eli Lilly And Co., Indianapolis | MORPHOLINO-N-ETHYL ESTER PRODROGEN VON INDOL sPLA 2 HEMMER |
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| CA2468202A1 (en) | 2001-12-12 | 2003-06-19 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating hsp90 binding activity |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| CN101103026A (zh) | 2005-01-14 | 2008-01-09 | 健亚生物科技公司 | 用于治疗病毒感染的吲哚衍生物 |
| US20060194835A1 (en) | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
| FR2928645A1 (fr) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| EP2293671A4 (en) | 2008-06-03 | 2012-03-21 | Siga Technologies Inc | SMALL MOLECULAR INHIBITORS FOR TREATING OR PREVENTING DENGUE INFECTIONS |
| BRPI0917394A2 (pt) * | 2008-08-18 | 2019-09-24 | Univ Yale | moduladores de mif |
| EP2331499B1 (en) | 2008-08-19 | 2016-09-21 | Janssen Pharmaceutica NV | Cold menthol receptor antagonists |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| CN102712632A (zh) | 2010-01-15 | 2012-10-03 | 吉里德科学公司 | 黄病毒科病毒的抑制剂 |
| JP2013523657A (ja) | 2010-03-26 | 2013-06-17 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのインダゾリル‐ピリミジン |
| JP5716205B2 (ja) | 2011-03-29 | 2015-05-13 | 学校法人日本大学 | グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法 |
| GB201116559D0 (en) * | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| JP6452119B2 (ja) | 2013-10-23 | 2019-01-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用 |
| TWI688564B (zh) | 2014-01-31 | 2020-03-21 | 美商必治妥美雅史谷比公司 | 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物 |
| CA2949981C (en) | 2014-06-04 | 2023-03-14 | Fred Hutchinson Cancer Research Center | Expansion and engraftment of stem cells using notch 1 and/or notch 2 agonists |
| KR102391259B1 (ko) | 2014-06-04 | 2022-04-26 | 암젠 인크 | 포유류 세포 배양물을 회수하는 방법 |
| ES2711117T3 (es) * | 2014-10-01 | 2019-04-30 | Janssen Pharmaceuticals Inc | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue |
| SI3201176T1 (sl) | 2014-10-01 | 2019-05-31 | Janssen Pharmaceuticals, Inc. | Mono-ali di-substituirani derivati indola kot inhibitorji replikacije virusa denga |
| NO2721243T3 (es) | 2014-10-01 | 2018-10-20 | ||
| ES2896198T3 (es) | 2014-10-10 | 2022-02-24 | Univ Rutgers | Cebadores y sondas de reacción en cadena de polimerasa para Mycobacterium tuberculosis |
| JOP20150335B1 (ar) * | 2015-01-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| JOP20160086B1 (ar) * | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| AU2016296923B2 (en) | 2015-07-22 | 2019-02-21 | Board Of Regents, The University Of Texas System | Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| RU2761212C2 (ru) | 2015-11-03 | 2021-12-06 | Зоэтис Сервисиз Ллс | Полимерные композиты, полученные по способу золь-гель, и их применение |
| JP6888021B2 (ja) | 2016-03-31 | 2021-06-16 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | デングウイルス複製阻害剤としての置換インドール誘導体 |
| CA3019298C (en) | 2016-03-31 | 2023-08-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3436436B1 (en) | 2016-03-31 | 2022-05-11 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| CR20180494A (es) | 2016-04-01 | 2019-01-29 | Janssen Pharmaceuticals Inc | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue |
| MA43603A1 (fr) | 2016-04-01 | 2019-03-29 | Amgen Inc | Récepteurs chimériques et leurs procédés d'utilisation |
| EP3436479A1 (en) | 2016-04-01 | 2019-02-06 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| KR102411744B1 (ko) | 2016-04-01 | 2022-06-21 | 바스프 에스이 | 바이시클릭 화합물 |
| CN109069512B (zh) | 2016-04-01 | 2022-06-14 | 西格诺药品有限公司 | 取代的氨基嘌呤化合物、其组合物以及相关治疗方法 |
| IL303785A (en) | 2016-04-01 | 2023-08-01 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| KR102625988B1 (ko) | 2017-05-22 | 2024-01-16 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체 |
| CR20190531A (es) | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
-
2016
- 2016-05-03 JO JOP/2016/0086A patent/JOP20160086B1/ar active
- 2016-05-04 EP EP16723965.6A patent/EP3294738B1/en active Active
- 2016-05-04 MX MX2020011156A patent/MX2020011156A/es unknown
- 2016-05-04 LT LTEP16723965.6T patent/LT3294738T/lt unknown
- 2016-05-04 KR KR1020177031660A patent/KR102610491B1/ko active IP Right Grant
- 2016-05-04 SI SI201631214T patent/SI3294738T1/sl unknown
- 2016-05-04 US US15/571,930 patent/US10696632B2/en active Active
- 2016-05-04 CR CR20200152A patent/CR20200152A/es unknown
- 2016-05-04 CA CA2981845A patent/CA2981845C/en active Active
- 2016-05-04 EP EP21159479.1A patent/EP3896072B1/en active Active
- 2016-05-04 RS RS20210800A patent/RS62029B1/sr unknown
- 2016-05-04 BR BR112017023904-3A patent/BR112017023904A2/pt not_active Application Discontinuation
- 2016-05-04 SG SG10201900315SA patent/SG10201900315SA/en unknown
- 2016-05-04 ES ES16723965T patent/ES2877404T3/es active Active
- 2016-05-04 CN CN202110222667.6A patent/CN113045476A/zh active Pending
- 2016-05-04 UA UAA201711845A patent/UA121332C2/uk unknown
- 2016-05-04 HU HUE16723965A patent/HUE054724T2/hu unknown
- 2016-05-04 WO PCT/EP2016/059975 patent/WO2016180696A1/en active Application Filing
- 2016-05-04 MD MDE20180272T patent/MD3294738T2/ro unknown
- 2016-05-04 CN CN202010168278.5A patent/CN111303000B/zh active Active
- 2016-05-04 MX MX2017014293A patent/MX2017014293A/es unknown
- 2016-05-04 PE PE2017002377A patent/PE20180232A1/es unknown
- 2016-05-04 DK DK16723965.6T patent/DK3294738T3/da active
- 2016-05-04 JP JP2017557923A patent/JP6752821B2/ja active Active
- 2016-05-04 ES ES21159479T patent/ES2941674T3/es active Active
- 2016-05-04 CN CN201680026606.XA patent/CN107873022B/zh active Active
- 2016-05-04 KR KR1020217011966A patent/KR102610493B1/ko active IP Right Grant
- 2016-05-04 PL PL16723965T patent/PL3294738T3/pl unknown
- 2016-05-04 EA EA201792429A patent/EA034978B1/ru unknown
- 2016-05-04 PE PE2021001440A patent/PE20221579A1/es unknown
- 2016-05-04 CR CR20170490A patent/CR20170490A/es unknown
- 2016-05-04 AU AU2016259677A patent/AU2016259677B2/en active Active
- 2016-05-05 TW TW109121289A patent/TWI744963B/zh active
- 2016-05-05 TW TW105113912A patent/TWI725969B/zh active
- 2016-05-06 UY UY0001039706A patent/UY39706A/es not_active Application Discontinuation
- 2016-05-06 UY UY0001036674A patent/UY36674A/es unknown
-
2017
- 2017-11-01 SV SV2017005557A patent/SV2017005557A/es unknown
- 2017-11-02 GT GT201700234A patent/GT201700234A/es unknown
- 2017-11-02 PH PH12017502000A patent/PH12017502000A1/en unknown
- 2017-11-05 IL IL255430A patent/IL255430B/en active IP Right Grant
- 2017-11-07 CL CL2017002817A patent/CL2017002817A1/es unknown
- 2017-11-07 EC ECIEPI201773878A patent/ECSP17073878A/es unknown
- 2017-11-07 NI NI201700137A patent/NI201700137A/es unknown
- 2017-11-30 CO CONC2017/0012381A patent/CO2017012381A2/es unknown
-
2018
- 2018-09-13 HK HK18111747.3A patent/HK1252446A1/zh unknown
- 2018-09-14 HK HK18111805.2A patent/HK1252496A1/zh unknown
-
2020
- 2020-02-20 IL IL272814A patent/IL272814B/en active IP Right Grant
- 2020-04-13 JP JP2020071412A patent/JP6898493B2/ja active Active
- 2020-05-05 ZA ZA2020/02435A patent/ZA202002435B/en unknown
- 2020-05-13 US US15/930,738 patent/US10919854B2/en active Active
- 2020-11-19 AU AU2020273314A patent/AU2020273314B2/en active Active
- 2020-12-31 US US17/139,703 patent/US11827602B2/en active Active
-
2021
- 2021-04-28 HR HRP20210675TT patent/HRP20210675T1/hr unknown
- 2021-05-10 JO JOP/2021/0109A patent/JOP20210109A1/ar unknown
- 2021-06-09 JP JP2021096927A patent/JP7132399B2/ja active Active
- 2021-07-06 CY CY20211100607T patent/CY1124548T1/el unknown
-
2022
- 2022-03-25 EC ECSENADI202223220A patent/ECSP22023220A/es unknown
- 2022-08-24 JP JP2022133239A patent/JP7451626B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002817A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2018002784A1 (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| CO2018003369A2 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue | |
| CO2018003471A2 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2018002729A1 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| CL2018002758A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue. | |
| CL2017000782A1 (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| CL2018002718A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CR20190446A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue | |
| CL2017000742A1 (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| UY36518A (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| AR106029A1 (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue |